Oncol Lett 28: [Related article:] 302, 2024; DOI:
10.3892/ol.2024.14435
Following the publication of this article, the
authors have realized that there were a few errors contained
therein that they neglected to correct before the paper was
published. These are listed as follows:
i) First, in the Abstract, the sentences commencing
on line 17, some factually incorrect information was provided. The
remainder of the Abstract should have read as follows (the changed
text is highlighted in bold): “In univariate analysis, OS
was inferior in patients with non-OCCC and OCCC exhibiting
TFPI2 levels ≥201 pg/ml (P<0.001) and ≥255 pg/ml (P=0.036),
respectively. Similarly, progression-free survival (PFS) was
significantly inferior in patients with non-OCCC and OCCC
with TFPI2 levels ≥201 pg/ml and ≥255 pg/ml (both P<0.001),
respectively. Multivariate analysis further confirmed that OS was
significantly inferior in patients with non-OCCC who had
TFPI2 levels ≥201 pg/ml (P=0.021), whereas PFS was inferior
in patients with OCCC who had TFPI2 levels ≥255 pg/ml (P=0.020).
These findings indicate that TFPI2 may serve as a potential
prognostic biomarker for ovarian carcinoma.
ii) Secondly, the following revision of the text was
necessary for the Discussion, p. 5, right-hand column, final
paragraph, the second sentence: “TFPI2 levels ≥201 pg/ml for
predicting OS for non-OCCC and ≥255 pg/ml for predicting OS for
OCCC were the cut-off values.”
The authors sincerely apologize for the errors that
were present in the text for the Abstract and Discussion, thank the
Editor of Oncology Letters for allowing them the opportunity
to publish this Corrigendum, and regret any inconvenience that
these mistakes may have caused.
